NCT01204138View on ClinicalTrials.gov

Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2011

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Apremilast

Apremilast 30mg BID

DRUG

Placebo

Placebo BID

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Stanford University

OTHER